A Phase 4, Open-Label Study of the Pharmacokinetics and Safety of Cambia (Diclofenac Potassium for Oral Solution) for the Acute Treatment of Migraine Attacks With or Without Aura in Pediatric Subjects (Ages 12-17 Years)
Phase of Trial: Phase IV
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Diclofenac potassium (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- Sponsors DepoMed
- 10 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 10 Dec 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Feb 2016 according to ClinicalTrials.gov record.
- 10 Dec 2015 Status changed from recruiting to active, no longer recruiting according to ClinicalTrials.gov record.